1007883-29-5

Basic information

• Product Name: 2-broMo-1-(2-chloropyriMidin-5-yl)ethanone
• Synonyms: 2-broMo-1-(2-chloropyriMidin-5-yl)ethanone;2-bromo-1-(2-chloro-5-pyrimidinyl)ethanone
• CAS NO: 1007883-29-5
• Molecular Formula: C6H4BrClN2O
• Molecular Weight: 235.46576
• EINECS: -0
• Mol File: 1007883-29-5.mol

Chemical Properties

• Boiling Point: 356.9±17.0 °C(Predicted)
• Appearance: /
• Density: 1.776±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: -3.60±0.22(Predicted)
• CAS DataBase Reference: 2-broMo-1-(2-chloropyriMidin-5-yl)ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-broMo-1-(2-chloropyriMidin-5-yl)ethanone(1007883-29-5)
• EPA Substance Registry System: 2-broMo-1-(2-chloropyriMidin-5-yl)ethanone(1007883-29-5)

Safety Data

• Hazardous Substances Data: 1007883-29-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(2-chloropyrimidin-5-yl)ethanone is used as a building block in organic synthesis for the production of various biologically active molecules. Its unique structure allows for the introduction of specific functional groups into organic molecules, making it a valuable reagent in the development of new pharmaceuticals.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Bromo-1-(2-chloropyrimidin-5-yl)ethanone serves as a key intermediate in the synthesis of agrochemicals. Its ability to be incorporated into complex molecular structures contributes to the creation of effective pesticides and other agricultural chemicals designed to protect crops and enhance yield.
Used in Medicinal Chemistry Research:
As a reagent in medicinal chemistry, 2-Bromo-1-(2-chloropyrimidin-5-yl)ethanone is utilized for the exploration and development of novel drug candidates. Its versatility in organic synthesis facilitates the design and synthesis of potential therapeutic agents with specific pharmacological properties.
Used in Organic Synthesis:
2-Bromo-1-(2-chloropyrimidin-5-yl)ethanone is employed as a versatile reagent in organic synthesis, enabling the creation of a wide range of chemical compounds. Its unique functional groups make it suitable for various synthetic routes, including the formation of new bonds and the modification of existing ones, ultimately leading to the production of diverse organic molecules with potential applications in various fields.

Upstream product

• 122372-20-7 2-chloro-5-(α-ethoxyvinyl)pyrimidine 
• 110100-00-0 1-(2-chloropyrimidin-5-yl)ethan-1-one 

Downstream Products

• 1007883-48-8 (S)-2-[5-(2-{4-[2-((S)-1-tert-butoxycarbonyl-pyrrolidin-2-yl)-3H-imidazol-4-yl]-phenyl}-pyrimidin-5-yl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir

The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1-6. However, these compounds exhibit

ANTIVIRAL COMPOUNDS

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HCV replication.

COMPOUNDS AND COMPOSITIONS AS MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 INHIBITORS

Provided herein are compounds, and pharmaceutical compositions comprising such compounds, wherein the compounds are inhibitors of mPGES-1 activity. Also provided herein are methods of using such compounds and composition to treat or prevent diseases or di

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.